

Ming-Kai Chen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11843236/publications.pdf>

Version: 2024-02-01

52
papers

2,885
citations

279778

23
h-index

243610

44
g-index

54
all docs

54
docs citations

54
times ranked

3623
citing authors

#	ARTICLE	IF	CITATIONS
1	Translocator protein 18kDa (TSPO): Molecular sensor of brain injury and repair. , 2008, 118, 1-17.		428
2	Imaging synaptic density in the living human brain. Science Translational Medicine, 2016, 8, 348ra96.	12.4	343
3	Assessing Synaptic Density in Alzheimer Disease With Synaptic Vesicle Glycoprotein 2A Positron Emission Tomographic Imaging. JAMA Neurology, 2018, 75, 1215.	9.0	304
4	Nigrostriatal dopamine system dysfunction and subtle motor deficits in manganese-exposed non-human primates. Experimental Neurology, 2006, 202, 381-390.	4.1	170
5	In vivo measurement of widespread synaptic loss in Alzheimer's disease with SV2A PET. Alzheimer's and Dementia, 2020, 16, 974-982.	0.8	170
6	Kinetic evaluation and test-retest reproducibility of [¹¹ C]UCB-J, a novel radioligand for positron emission tomography imaging of synaptic vesicle glycoprotein 2A in humans. Journal of Cerebral Blood Flow and Metabolism, 2018, 38, 2041-2052.	4.3	143
7	Peripheral benzodiazepine receptor imaging in CNS demyelination: functional implications of anatomical and cellular localization. Brain, 2004, 127, 1379-1392.	7.6	124
8	VMAT2 and dopamine neuron loss in a primate model of Parkinson's disease. Journal of Neurochemistry, 2008, 105, 78-90.	3.9	111
9	Evidence for Cortical Dysfunction and Widespread Manganese Accumulation in the Nonhuman Primate Brain following Chronic Manganese Exposure: A 1H-MRS and MRI Study. Toxicological Sciences, 2006, 94, 351-358.	3.1	110
10	Acute manganese administration alters dopamine transporter levels in the non-human primate striatum. NeuroToxicology, 2006, 27, 229-236.	3.0	87
11	Effects of age, BMI and sex on the glial cell marker TSPO – a multicentre [¹¹ C]PBR28 HRRT PET study. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2329-2338.	6.4	70
12	Manganese inhibits NMDA receptor channel function: Implications to psychiatric and cognitive effects. NeuroToxicology, 2007, 28, 1147-1152.	3.0	66
13	Imaging the Peripheral Benzodiazepine Receptor Response in Central Nervous System Demyelination and Remyelination. Toxicological Sciences, 2006, 91, 532-539.	3.1	61
14	The Utility of I-123 Pretherapy Scan in I-131 Radioiodine Therapy for Thyroid Cancer. Thyroid, 2012, 22, 304-309.	4.5	57
15	Synaptic density and cognitive performance in Alzheimer's disease: A PET imaging study with [¹¹ C]UCB-J. Alzheimer's and Dementia, 2022, 18, 2527-2536.	0.8	55
16	Association of A β 2 deposition and regional synaptic density in early Alzheimer's disease: a PET imaging study with [¹¹ C]UCB-J. Alzheimer's Research and Therapy, 2021, 13, 11.	6.2	53
17	Reduced synaptic vesicle protein 2A binding in temporal lobe epilepsy: A [¹¹ C]UCB-J positron emission tomography study. Epilepsia, 2020, 61, 2183-2193.	5.1	51
18	Assessment of population-based input functions for Patlak imaging of whole body dynamic 18F-FDG PET. EJNMMI Physics, 2020, 7, 67.	2.7	45

#	ARTICLE	IF	CITATIONS
19	The need of standardization and of large clinical studies in an emerging indication of [¹⁸ F]FDG PET: the autoimmune encephalitis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 353-357.	6.4	44
20	Comparison of [¹¹ C]UCB-J and [¹⁸ F]FDG PET in Alzheimer's disease: A tracer kinetic modeling study. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021, 41, 2395-2409.	4.3	43
21	An extended simplified reference tissue model for the quantification of dynamic PET with amphetamine challenge. <i>NeuroImage</i> , 2006, 33, 550-563.	4.2	42
22	In Vivo Imaging of Peripheral Benzodiazepine Receptors in Mouse Lungs: A Biomarker of Inflammation. <i>Molecular Imaging</i> , 2005, 4, 7290.2005.05133.	1.4	33
23	PET imaging of mGluR5 in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 15.	6.2	29
24	Imaging of Synaptic Density in Neurodegenerative Disorders. <i>Journal of Nuclear Medicine</i> , 2022, 63, 60S-67S.	5.0	29
25	Binding of the synaptic vesicle radiotracer [¹¹ C]UCB-J is unchanged during functional brain activation using a visual stimulation task. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021, 41, 1067-1079.	4.3	28
26	Association of entorhinal cortical tau deposition and hippocampal synaptic density in older individuals with normal cognition and early Alzheimer's disease. <i>Neurobiology of Aging</i> , 2022, 111, 44-53.	3.1	25
27	Norepinephrine transporter availability in brown fat is reduced in obesity: a human PET study with [¹¹ C] MRB. <i>International Journal of Obesity</i> , 2020, 44, 964-967.	3.4	18
28	Improved discrimination between benign and malignant LDCT screening-detected lung nodules with dynamic over static [¹⁸ F]FDG PET as a function of injected dose. <i>Physics in Medicine and Biology</i> , 2018, 63, 175015.	3.0	17
29	Partial volume correction analysis for [¹¹ C]UCB-J PET studies of Alzheimer's disease. <i>NeuroImage</i> , 2021, 238, 118248.	4.2	17
30	Generation of parametric K_{i} images for FDG PET using two 5-min scans. <i>Medical Physics</i> , 2021, 48, 5219-5231.	3.0	16
31	Neuroimaging in Dementias. <i>Seminars in Neurology</i> , 2019, 39, 188-199.	1.4	14
32	Generation of synthetic PET images of synaptic density and amyloid from [¹⁸ F]FDG images using deep learning. <i>Medical Physics</i> , 2021, 48, 5115-5129.	3.0	12
33	Determining the Minimal Required Radioactivity of [¹⁸ F]FDG for Reliable Semiquantification in PET/CT Imaging: A Phantom Study. <i>Journal of Nuclear Medicine Technology</i> , 2016, 44, 26-30.	0.8	11
34	PET Imaging of Synaptic Vesicle Protein 2A. , 2021, , 993-1019.		10
35	Recombinant human thyroid-stimulating hormone as an alternative for thyroid hormone withdrawal in thyroid cancer management. <i>Current Opinion in Oncology</i> , 2010, 22, 6-10.	2.4	8
36	What is the role of dosimetry in patients with advanced thyroid cancer?. <i>Current Opinion in Oncology</i> , 2015, 27, 33-37.	2.4	8

#	ARTICLE	IF	CITATIONS
37	Deep learning-based attenuation correction for whole-body PET – a multi-tracer study with 18F-FDG, 68Ga-DOTATATE, and 18F-Fluciclovine. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 3086-3097.	6.4	8
38	Synthesizing Multi-tracer PET Images for Alzheimer's Disease Patients Using a 3D Unified Anatomy-Aware Cyclic Adversarial Network. Lecture Notes in Computer Science, 2021, , 34-43.	1.3	6
39	PET Image Denoising Using a Deep-Learning Method for Extremely Obese Patients. IEEE Transactions on Radiation and Plasma Medical Sciences, 2022, 6, 766-770.	3.7	6
40	ICA-derived sources of synaptic density PET ([11 C]UCBâ€) relate to cognitive impairment severity in Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e041197.	0.8	3
41	Association between cerebrospinal fluid biomarkers of neurodegeneration and PET measurements of synaptic density in Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e044211.	0.8	2
42	P1â€469: PET IMAGING OF METABOTROPIC GLUTAMATE RECEPTOR 5 BINDING IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P501.	0.8	1
43	In vivo measurement of widespread synaptic loss and associated tau accumulation in early Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e037791.	0.8	1
44	Validation of a simplified tissue-to-reference ratio measurement using SUVR for the assessment of synaptic density alterations in Alzheimer's disease using [11 C]UCBâ€ PET. Alzheimer's and Dementia, 2020, 16, e045928.	0.8	1
45	P2â€365: PET IMAGING OF SYNAPTIC DENSITY (SYNAPTIC VESICLE GLYCOPROTEIN 2A, SV2A) IN ALZHEIMER'S DISEASE: INITIAL EXPERIENCE. Alzheimer's and Dementia, 2018, 14, P832.	0.8	0
46	ICâ€04â€03: PET IMAGING OF METABOTROPIC GLUTAMATE RECEPTOR 5 BINDING IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P8.	0.8	0
47	ICâ€Pâ€183: PET IMAGING OF SYNAPTIC DENSITY (SYNAPTIC VESICLE GLYCOPROTEIN 2A, SV2A) IN ALZHEIMER'S DISEASE: INITIAL EXPERIENCE. Alzheimer's and Dementia, 2018, 14, P152.	0.8	0
48	P4â€481: ASSOCIATION BETWEEN ENTORHINAL CORTICAL TAU ACCUMULATION AND HIPPOCAMPAL SYNAPTIC DENSITY IN OLDER INDIVIDUALS WITH NORMAL COGNITION AND EARLY ALZHEIMER'S DISEASE: PRELIMINARY EXPERIENCE. Alzheimer's and Dementia, 2019, 15, P1497.	0.8	0
49	ICâ€Pâ€140: ASSOCIATION BETWEEN MGLUR5 AND SYNAPTIC DENSITY: A MULTIâ€TRACER STUDY IN HEALTHY AGING AND ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P115.	0.8	0
50	Association between cerebral amyloid accumulation and synaptic density in Alzheimer's disease: A multitracer PET study. Alzheimer's and Dementia, 2020, 16, e043631.	0.8	0
51	Determining the Minimal Required Ultra-Low-Dose CT Dose Level for Reliable Attenuation Correction of ¹⁸ F-FDG PET/CT: A Phantom Study. Journal of Nuclear Medicine Technology, 2022, 50, 126-131.	0.8	0
52	Use of (18)F-fluorodeoxyglucose positron emission tomography-computed tomography to aid in diagnosing intestinal adenocarcinoma in 2 rhesus macaques (Macaca mulatta). Comparative Medicine, 2014, 64, 211-20.	1.0	0